Tyrosine kinase inhibitors (TKIs) incorporate a broad range of small molecule therapeutics which may target oncogenes (e.g. Epidermal Growth Factor Receptor, EGFR) or other targets in the tumour microenvironment (e.g. Vascular Endothelial Growth Factor, VEGF). The gene discussed is EGFR; the disease is neoplasm.